Melanin-Concentrating Hormone
What the Research Actually Shows
Human: 0 studies, 3 groups · Animal: 2 · In Vitro: 0
The neuropeptide that selectively controls REM sleep—produced by neurons intermingled with orexin's wake cells in the lateral hypothalamus, linked to cataplexy in narcolepsy models, and the target of stalled drug programs in both obesity and sleep medicine
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
MCH is the neuropeptide that controls REM sleep—the stage where you dream. Its neurons fire almost exclusively during REM and are virtually silent during wakefulness. When scientists activated these neurons with light in mice, REM sleep increased selectively without affecting other sleep stages. In mice engineered to lack orexin (modeling narcolepsy), activating MCH neurons caused cataplexy—the sudden muscle collapse that narcolepsy patients experience. An MCH receptor blocker nearly eliminated the cataplexy. This is some of the cleanest preclinical evidence in sleep medicine. But no MCH-targeting drug has been tested in people. Drug programs for obesity using MCH receptor blockers stalled. A narcolepsy program was announced but has not reported results. The biology is elegant. The pharmacology has not arrived.
In the lateral hypothalamus, two populations of neuropeptide-producing neurons sit physically intermingled but functionally opposed. Orexin neurons keep you awake—their loss causes narcolepsy. MCH neurons promote REM sleep—their activation selectively increases dreaming sleep without affecting NREM stages. The same brain region, separated by microns, houses the master controllers of wakefulness and REM sleep. Orexin has generated three FDA-approved drugs. MCH has generated none.
Melanin-concentrating hormone is a 19-amino-acid cyclic neuropeptide originally discovered in salmon, where it lightens skin color by concentrating melanin pigment granules. In mammals, it has nothing to do with skin color. It regulates REM sleep, appetite, and energy balance through the MCHR1 receptor—a Gi-coupled GPCR expressed throughout the brain and periphery.
The sleep story is the most compelling. Jego et al. (2013; PMID 24048840) used optogenetics to demonstrate that MCH neuron activation selectively increases REM sleep in mice—the first causal demonstration that a specific neuropeptide system controls REM independently of NREM. Naganuma et al. (2018; PMID 30149182) then showed that in orexin-knockout mice (a narcolepsy model), MCH neuron activation drove cataplexy and abnormal REM intrusions—and that an MCHR1 antagonist nearly eliminated both symptoms. This finding positioned MCH receptor blockade as a potential narcolepsy therapy. Harmony Biosciences announced an IND filing for HBS-102 (MCHR1 antagonist for narcolepsy) in 2021, but no clinical data has been published. This article examines what MCH does, why the REM selectivity matters, and why a peptide with such clean biology has struggled to become a drug.
In This Article
Quick Facts: Melanin-Concentrating Hormone at a Glance
Type
Endogenous neuropeptide, 19 amino acids (human), cyclic (single disulfide bond)
Also Known As
MCH, Melanin-Concentrating Hormone, PMCH (prepro-MCH gene)
Generic Name
None. No pharmaceutical product exists. MCHR1 antagonists attempted for obesity (none approved). HBS-102 announced for narcolepsy (no clinical data).
Route
ICV injection (animal models). No human dosing protocol established for MCH peptide. MCHR1 antagonists: oral (small molecules, preclinical/early clinical).
Molecular Weight
~2,387 Da (human 19-aa form)
Peptide Sequence
Human MCH: 19 amino acids with a single disulfide bridge forming a cyclic structure. Originally 17 amino acids in salmon (MCH function: melanin granule aggregation in melanophores). Mammalian MCH gained two amino acids and lost the skin-color function entirely.
Endogenous Origin
Yes. Produced by approximately 10,000 neurons in the lateral hypothalamus (LH) and zona incerta. These neurons are physically intermingled with, but functionally opposite to, orexin neurons in the same region. MCH neurons project throughout the CNS—cortex, hippocampus, brainstem, spinal cord.
Primary Molecular Function
Binds MCHR1 (Gi/Go-coupled GPCR → inhibits adenylate cyclase → reduces cAMP → suppresses neuronal activity). MCHR2 exists in humans but MCHR1 is the principal functional receptor. MCHR1 activation on wake-promoting neurons suppresses their activity during REM sleep, maintaining the REM state.
Active Fragment
Full-length MCH (1–19) is the primary active form. The disulfide bond (Cys7–Cys16) is required for full receptor binding and biological activity.
Brand Name
None. No MCH-targeting therapeutic is approved.
Related Compound Relationship
MCH neurons are intermingled with orexin neurons in the lateral hypothalamus but have opposing functions: orexin promotes wakefulness, MCH promotes REM sleep. Galanin (also in Cluster J) promotes NREM/SWS through the VLPO—a different mechanism and different sleep stage than MCH's REM promotion.
Clinical Programs
MCHR1 antagonists for obesity: multiple pharma programs (GlaxoSmithKline, Roche, others) entered preclinical/early clinical development in 2000s—none approved, most discontinued. HBS-102 (Harmony Biosciences): MCHR1 antagonist for narcolepsy, IND announced 2021, no Phase 2 data published. No MCH agonist in clinical development.
WADA Status
Not on the Prohibited List
Community Interest
Essentially none. MCH is not available from consumer peptide vendors. No self-experimentation protocols exist. Academic interest is high in sleep neuroscience and obesity research.
FDA Status
Not approved. No MCH-targeting drug has completed a human efficacy trial for any indication.
Half-Life
Unknown in humans. MCH is a 19-amino-acid cyclic peptide; plasma half-life estimated at minutes based on similar peptides.
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is MCH?
Pronunciation: em-see-aitch (melanin-concentrating HORMONE)
REM sleep is strange. Your brain is as electrically active as it is during wakefulness—vivid dreaming, emotional processing, memory consolidation—but your body is paralyzed, your temperature regulation is suspended, and your voluntary muscles (except the eyes and diaphragm) are locked in atonia. It is a physiological state unlike any other, and for most of the history of sleep science, no one knew which molecule controlled it. MCH is the strongest candidate.
Melanin-concentrating hormone is a 19-amino-acid cyclic neuropeptide with a misleading name and a fascinating evolutionary journey. In fish, MCH does exactly what its name says—it concentrates melanin granules within melanophores, making the skin lighter (the opposite of melanocyte-stimulating hormone, which disperses melanin and darkens skin). When MCH was found in mammalian brains in the 1990s, researchers expected it to play a similar pigmentation role. It does not. Mammals repurposed this ancient peptide for feeding behavior, energy balance, and—most importantly for Cluster J—the selective promotion of REM sleep.
MCH neurons reside in the lateral hypothalamus and zona incerta—about 10,000 in the human brain. They are physically intermingled with orexin neurons, sharing the same anatomical neighborhood but operating on opposite sides of the sleep-wake equation. Orexin neurons fire during wakefulness and promote alertness. MCH neurons fire maximally during REM sleep and are virtually silent during wakefulness and NREM sleep. This reciprocal arrangement within a single brain region is one of the most elegant organizational principles in sleep neuroscience.
PLAIN ENGLISH
MCH is a peptide that controls your dream sleep—REM sleep. Despite its name (which comes from its skin-lightening role in fish), it has nothing to do with skin color in humans. About 10,000 brain cells make MCH, and they sit right next to the orexin neurons that keep you awake. When the orexin cells are active, you are awake. When the MCH cells are active, you are in REM sleep. These two populations of neurons, sitting side by side, control opposite states of consciousness.
Origins and Discovery
MCH was first isolated from chum salmon pituitary glands in 1983 by Kawauchi and colleagues, who were studying the hormonal control of fish skin color. In salmon, MCH is a 17-amino-acid peptide that causes melanin granules to aggregate within melanophores—lightening the skin. This is a well-characterized neuroendocrine function in teleost fish, useful for camouflage.
The mammalian MCH gene was cloned in the early 1990s. The mammalian peptide gained two amino acids (19 total) and lost the skin-color function entirely—mammals do not have melanophores. For several years, mammalian MCH was an orphan peptide in search of a function. The first clue came in 1996, when Qu et al. demonstrated that ICV MCH injection in rats potently stimulated feeding—making MCH one of several hypothalamic peptides (along with NPY and orexin) implicated in appetite regulation.
The sleep chapter began with the observation that MCH neurons are maximally active during REM sleep—a firing pattern inconsistent with a purely appetite-related function (you do not eat while sleeping). The definitive experiment came in 2013 when Jego et al. (PMID 24048840) used optogenetics in mice: activating MCH neurons with light selectively increased REM sleep duration and frequency without affecting NREM sleep or wakefulness. This was the first causal demonstration that a specific identified neuron type controls REM sleep.
The narcolepsy connection followed in 2018 when Naganuma et al. (PMID 30149182) showed that MCH neuron activation in orexin-knockout mice (which model narcolepsy) produced cataplexy and abnormal REM intrusions—and that MCHR1 receptor blockade nearly eliminated these symptoms. This positioned MCHR1 antagonism as a potential narcolepsy treatment.
PLAIN ENGLISH
MCH was discovered in salmon in 1983 as a skin-lightening hormone. When scientists found it in mammalian brains, they initially thought it was about appetite—injecting it made rats eat more. Then they noticed that MCH neurons fire almost exclusively during REM sleep. In 2013, optogenetics proved that activating these neurons causes REM sleep. In 2018, blocking the MCH receptor eliminated cataplexy in narcolepsy-model mice. A peptide discovered for fish camouflage turned out to control human dreaming sleep.
Mechanism of Action
REM Sleep Selectivity
MCH's mechanism in REM sleep operates through selective suppression of wake-promoting centers during the REM state:
MCH neuron firing pattern: MCH neurons in the lateral hypothalamus are virtually silent during wakefulness and NREM sleep. They begin firing at the onset of REM sleep and reach maximal activity during sustained REM episodes. This firing pattern is the most REM-selective of any identified neuron population.
Target inhibition during REM: MCH neurons are GABAergic (they release GABA) and co-release MCH. They project to and inhibit wake-promoting nuclei including the locus coeruleus (norepinephrine), tuberomammillary nucleus (histamine), and dorsal raphe (serotonin). During REM, these wake centers must be silenced—MCH neurons provide that silencing, complementing the REM-on circuitry of the sublaterodorsal nucleus (glutamatergic REM generator) and the ventral medullary neurons (which produce REM atonia).
MCHR1 signaling: MCHR1 is a Gi/Go-coupled receptor. Activation → inhibition of adenylate cyclase → reduced cAMP → reduced PKA activity → decreased neuronal excitability. This is a classical inhibitory neuropeptide mechanism. The net effect is suppression of wake-promoting neuronal firing during REM episodes.
The Orexin-MCH Yin-Yang
The lateral hypothalamus contains both orexin and MCH neurons, but their activity patterns are reciprocal:
| State | Orexin Neurons | MCH Neurons |
|---|---|---|
| Wakefulness | Active | Silent |
| NREM sleep | Reduced | Low/Variable |
| REM sleep | Silent | Maximally active |
Mutual inhibition between these populations contributes to sleep-wake state stability. When orexin neurons are destroyed (narcolepsy type 1), the MCH neurons lose their normal constraint—potentially becoming overactive during inappropriate times and contributing to the REM dysregulation that characterizes narcolepsy (cataplexy, sleep paralysis, hypnagogic hallucinations, sleep-onset REM periods).
Energy Balance
MCH is potently orexigenic—it stimulates feeding, particularly high-fat food preference. MCH-overexpressing transgenic mice develop obesity. MCH-knockout mice are lean, hyperactive, and resistant to diet-induced obesity. This dual role (REM sleep + appetite) makes pharmacological targeting complex: an MCHR1 antagonist designed to treat narcolepsy would also reduce appetite and promote weight loss. Whether this is a feature or a bug depends on the patient population.
PLAIN ENGLISH
MCH neurons fire only during REM sleep—they are the most REM-specific brain cells known. When they fire, they release MCH and GABA to shut down the wake centers, helping maintain the REM state. These neurons sit right next to orexin neurons in the lateral hypothalamus, and the two populations take turns: orexin active during waking, MCH active during REM. In narcolepsy, orexin neurons are destroyed, and MCH neurons lose their normal check—potentially contributing to the REM intrusions (cataplexy, sleep paralysis) that define the disease. MCH also stimulates appetite, which complicates drug development.
Key Research Areas and Studies
MCH Optogenetic REM Promotion (Jego et al., 2013)
Study: Optogenetic identification of a rapid eye movement sleep modulatory circuit in the hypothalamus. PMID: 24048840 Design: Channelrhodopsin-2 expression in MCH neurons of MCH-Cre mice. Optical stimulation during sleep with EEG/EMG recording. Key findings: Selective activation of MCH neurons increased REM sleep duration by ~50–70% and REM bout frequency. No effect on NREM sleep duration or wakefulness. Effect was mediated through MCH neuron projections to the tuberomammillary nucleus. Significance: First causal demonstration that a specific neuron type selectively controls REM sleep. Established MCH neurons as the primary REM-promoting cell population.
MCHR1 Antagonism in Narcolepsy Model (Naganuma et al., 2018)
Study: Orexin-deficient mice show elevated MCH neuron activity and cataplexy suppression by MCHR1 antagonism. PMID: 30149182 Design: Orexin-knockout mice (narcolepsy model) treated with MCHR1 antagonist SNAP 94847. Also optogenetic activation of MCH neurons in orexin-KO mice. Key findings: MCH neuron activation in orexin-KO mice dramatically increased cataplexy episodes and short-latency REM (SLREM) transitions. MCHR1 antagonist SNAP 94847 almost completely eliminated cataplexy and normalized REM latency. Effect was specific to the orexin-deficient state—MCHR1 antagonism had minimal effects on sleep in wild-type mice. Significance: The strongest preclinical evidence that MCHR1 antagonism could treat narcolepsy/cataplexy. The specificity to the orexin-deficient state suggests that MCH overactivity is a pathological consequence of orexin loss—not a normal sleep mechanism gone wrong.
MCH and Energy Balance (Ludwig et al., 2001; Qu et al., 1996)
MCH-overexpressing mice develop late-onset obesity, hyperphagia, and insulin resistance. MCH-knockout mice are lean, hypophagic, and have elevated metabolic rate. These opposing phenotypes established MCH as a potent orexigenic peptide and launched multiple MCHR1 antagonist programs for obesity treatment in the early 2000s. None advanced to approval—efficacy was modest, and the metabolic/sleep complexity of MCH signaling created challenging side-effect profiles.
PLAIN ENGLISH
Two landmark studies define MCH's clinical relevance. The 2013 optogenetics paper proved that turning on MCH neurons causes REM sleep selectively—no effect on other sleep stages. The 2018 paper showed that blocking the MCH receptor in narcolepsy-model mice almost completely eliminated cataplexy. That second finding is the most promising preclinical lead for narcolepsy treatment since the discovery of the orexin-narcolepsy link. Separate studies showed that MCH also controls appetite—mice engineered to overproduce MCH become obese, while those lacking it are lean.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “MCH selectively promotes REM sleep” | Optogenetic activation of MCH neurons in mice increases REM duration ~50–70% without affecting NREM or wakefulness (Jego et al., 2013, PMID 24048840). MCH neurons fire selectively during REM. | Preclinical Only |
| “MCH receptor blockade treats cataplexy” | MCHR1 antagonist SNAP 94847 nearly eliminated cataplexy in orexin-knockout mice (Naganuma et al., 2018, PMID 30149182). No human data. | Preclinical Only |
| “MCH is the REM sleep peptide” | MCH neurons show the most REM-selective firing pattern of any identified neuron population. Causal evidence from optogenetics supports a direct role. Other systems also contribute to REM regulation. | Preclinical Only |
| “MCHR1 antagonists can treat narcolepsy” | Preclinical evidence is strong. Harmony Biosciences announced IND for HBS-102 (2021). No clinical data published. | Preclinical Only |
| “MCH supplements improve sleep” | MCH is not available as a supplement. Even if it were, MCH also stimulates appetite and would need to reach the brain to affect sleep—peripheral administration would likely produce metabolic effects without sleep benefits. | Unsupported |
| “MCH controls appetite” | MCH-overexpressing mice are obese; MCH-KO mice are lean. ICV MCH stimulates feeding. Well-established in animal models. Human relevance supported by MCHR1 expression in feeding circuits. | Preclinical Only |
| “MCH and orexin neurons are physically adjacent” | Confirmed by immunohistochemistry—MCH and orexin neurons are intermingled in the lateral hypothalamus. They share anatomical space but have reciprocal firing patterns. | Supported |
| “MCH overactivity causes narcolepsy symptoms” | In orexin-KO mice (narcolepsy model), MCH neuron activation increases cataplexy. MCH may be overactive due to loss of orexin-mediated inhibition. Plausible mechanism. Animal data only. | Preclinical Only |
| “MCHR1 antagonists cause weight loss” | MCHR1 antagonists reduce food intake and body weight in rodent obesity models. Multiple pharma programs existed but none achieved clinical success. | Preclinical Only |
| “MCH has no role in NREM sleep” | MCH neuron activation did not significantly affect NREM duration in the Jego optogenetics study. MCH appears functionally specific to REM. However, absence of effect on NREM in one paradigm does not rule out all NREM involvement. | Preclinical Only |
| “MCH could explain REM sleep disorders” | MCH dysregulation could contribute to REM behavior disorder, REM intrusions, or excessive REM sleep. The hypothesis is consistent with the biology but untested in human sleep disorders. | Unsupported |
| “Blocking MCH would reduce dreaming” | MCHR1 antagonism reduces REM sleep in animal models. Whether this translates to reduced dreaming in humans is unknown—the relationship between REM and subjective dream experience is complex. | Unsupported |
The Human Evidence Landscape
There is no interventional human evidence for MCH. No human has received MCH or an MCH receptor modulator in a published clinical trial with reported results. MCH levels have been measured in human cerebrospinal fluid—interestingly, narcolepsy type 1 patients have normal CSF MCH levels despite losing orexin (suggesting MCH neurons are intact; the problem is loss of orexin-mediated inhibition of MCH neurons, not loss of MCH neurons themselves).
The Failed Obesity Programs
Multiple pharmaceutical companies developed MCHR1 antagonists for obesity in the early 2000s, motivated by the lean phenotype of MCH-knockout mice. GlaxoSmithKline, Roche, Amgen, and others invested in the space. None advanced to Phase 3. The reasons were a combination of modest efficacy, metabolic complexity, and the challenging regulatory environment for weight-loss drugs. These programs were not designed for sleep and provide limited insight into MCH's sleep-related potential.
The Narcolepsy Pipeline
The most promising clinical development is Harmony Biosciences' HBS-102 (MCHR1 antagonist for narcolepsy type 1). Harmony—the company that markets pitolisant (Wakix), a histamine H3 receptor inverse agonist for narcolepsy—announced IND preparation in 2021 based on the Naganuma et al. preclinical data. As of 2025, no Phase 2 data has been published or presented at major conferences.
The Translational Challenge
MCH's dual role in REM sleep and appetite creates a pharmacological puzzle. An MCHR1 antagonist for narcolepsy would reduce cataplexy and REM intrusions (desired) but would also suppress appetite and promote weight loss (potentially unwanted in some patients, potentially beneficial in others—narcolepsy patients have elevated BMI partly due to orexin loss). The challenge is developing a compound with the right pharmacokinetic profile: brain-penetrating enough for sleep circuit effects but with manageable metabolic consequences.
PLAIN ENGLISH
No MCH drug has been tested in humans and reported results. Drug companies tried MCH receptor blockers for weight loss in the 2000s—none worked well enough to get approved. Harmony Biosciences announced a narcolepsy program in 2021 based on the striking mouse data, but no clinical results have been published. The human evidence consists of measuring MCH levels in spinal fluid, which showed that narcolepsy patients have normal MCH (unlike their absent orexin)—meaning the MCH neurons are intact even when orexin neurons are destroyed.
Safety, Risks, and Limitations
No Human Safety Data
No MCH agonist or antagonist has published human safety data. The obesity MCHR1 antagonist programs may have generated safety data, but it is not publicly available.
Theoretical Risks
Appetite suppression (MCHR1 antagonism): Given MCH's potent orexigenic role, MCHR1 antagonists would be expected to reduce appetite. This could be beneficial (weight management) or adverse (unwanted weight loss) depending on context.
REM suppression (MCHR1 antagonism): An MCHR1 antagonist for cataplexy would also reduce normal REM sleep. REM sleep is important for emotional processing, memory consolidation, and cognitive function. The degree to which REM suppression would be tolerated in chronic use is unknown.
Metabolic effects: MCH modulates insulin sensitivity and glucose metabolism. MCHR1 antagonism could alter metabolic parameters—this was part of the complexity that challenged the obesity programs.
Delivery Considerations
MCH is a 19-amino-acid cyclic peptide. Peripheral administration would face enzymatic degradation and blood-brain barrier challenges. The clinical approach (MCHR1 antagonists) uses small molecules, not the peptide itself.
PLAIN ENGLISH
Since no MCH drug has been tested in people, we do not know the side effects. The main expected issues are reduced appetite (which could be good or bad) and reduced dream sleep (which might affect memory and mood). The drug development challenge is that MCH controls both REM sleep and appetite—blocking its receptor would affect both.
Legal and Regulatory Status
MCH has no regulatory status as a pharmaceutical. No MCH-targeting drug is FDA-approved. MCHR1 antagonists reached early clinical development for obesity but none were submitted for approval. HBS-102 (Harmony Biosciences, MCHR1 antagonist for narcolepsy) is at the IND stage without published clinical data.
Research-grade MCH is available from laboratory peptide suppliers for institutional use. It is not sold by consumer peptide vendors.
WADA does not list MCH on its Prohibited List.
Research Protocols and Formulation Considerations
Animal Research Protocols
| Parameter | Detail |
|---|---|
| Optogenetics (Jego) | ChR2 in MCH-Cre mice; optical stimulation at various frequencies during sleep |
| Pharmacology (Naganuma) | MCHR1 antagonist SNAP 94847 at 20 mg/kg IP in orexin-KO mice |
| ICV MCH | 0.5–5.0 mcg MCH in rats; increases feeding and modulates sleep architecture |
Storage
Research-grade MCH: lyophilized powder at −20°C (−4°F). Reconstituted in saline. Single disulfide bond requires proper handling.
Dosing in Published Research
The following table summarizes dosing protocols for Melanin-Concentrating Hormone as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Research Dosing
| Parameter | Detail |
|---|---|
| Route | ICV (animal), IP for MCHR1 antagonists (animal) |
| Animal ICV MCH | 0.5–5.0 mcg |
| MCHR1 antagonist (animal) | SNAP 94847: 20 mg/kg IP |
| Human dose | Does not exist — no human trial completed |
| Therapeutic | MCHR1 antagonists (small molecules), not MCH peptide |
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Melanin-Concentrating Hormone has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Why This Section Is Nearly Empty
MCH is not used in any self-experimentation community. It is not sold by consumer peptide vendors, has no established human dosing protocol, and presents complex pharmacology—it would simultaneously affect REM sleep and appetite. The clinical approach to targeting MCH uses small-molecule receptor antagonists, not the peptide itself. There are no forum discussions, community protocols, or anecdotal reports of MCH self-experimentation.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Melanin-Concentrating Hormone combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Melanin-Concentrating Hormone with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Melanin-Concentrating Hormone Compares
Melanin-Concentrating Hormone belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
What is melanin-concentrating hormone?
MCH is a 19-amino-acid cyclic neuropeptide produced by about 10,000 neurons in the lateral hypothalamus. Despite its name (from its skin-lightening role in fish), MCH in mammals regulates REM sleep and appetite. Its neurons fire selectively during REM sleep and are virtually silent during wakefulness.
Does MCH have anything to do with melanin or skin color?
In fish, yes—MCH concentrates melanin pigment granules, lightening the skin. In mammals, no. The mammalian peptide was repurposed during evolution for brain functions—REM sleep and feeding regulation. The name is a historical artifact from the 1983 discovery in salmon.
How does MCH control REM sleep?
MCH neurons release both GABA and MCH to inhibit wake-promoting brain centers (locus coeruleus, tuberomammillary nucleus, raphe nuclei) specifically during REM sleep. This suppression allows the REM state to be maintained—dreams occur, muscles are paralyzed, and the brain processes emotions and memories undisturbed by wakefulness.
Is MCH the opposite of orexin?
Functionally, yes. Orexin neurons in the lateral hypothalamus promote wakefulness. MCH neurons in the same region promote REM sleep. Their firing patterns are reciprocal—orexin active during wake, MCH active during REM. They are physically intermingled in the same brain area but control opposite states.
Could blocking MCH help with narcolepsy?
The preclinical evidence is strong. In mice lacking orexin (narcolepsy model), an MCH receptor blocker nearly eliminated cataplexy. Harmony Biosciences announced a narcolepsy drug program (HBS-102) based on this finding. No human data has been published.
Can I take MCH as a sleep supplement?
No. MCH is not available as a consumer product. Even theoretically, taking MCH would increase REM sleep and stimulate appetite simultaneously. It would require brain delivery to affect sleep, and peripheral administration would primarily cause metabolic effects.
Why did the obesity drugs targeting MCH fail?
MCHR1 antagonists for obesity showed modest weight loss in animal models but did not demonstrate sufficient efficacy in early clinical development to justify Phase 3 trials. The complexity of MCH signaling—affecting sleep, appetite, metabolism, and mood—made it difficult to achieve a clean therapeutic profile for weight loss alone.
Does MCH affect dreaming?
MCH selectively promotes the REM sleep stage during which most vivid dreaming occurs. Whether MCH directly influences dream content or intensity is unknown—the relationship between neuronal activity patterns and subjective dream experience is one of the unsolved questions in consciousness research.
Is MCH related to the narcolepsy drug Wakix?
Indirectly. Harmony Biosciences, which markets Wakix (pitolisant, a histamine H3 receptor inverse agonist for narcolepsy), is also developing HBS-102 (an MCHR1 antagonist for narcolepsy). The drugs target different neurotransmitter systems but the same disease. Pitolisant enhances histamine signaling to promote wakefulness. HBS-102 would block MCH signaling to reduce REM intrusions and cataplexy.
Do people with narcolepsy have normal MCH levels?
Yes. Narcolepsy type 1 patients have normal CSF MCH levels despite undetectable orexin. The MCH neurons are intact; the problem is that destroyed orexin neurons no longer inhibit MCH neurons, leading to potential MCH overactivity—particularly during inappropriate wake-to-REM transitions that manifest as cataplexy.
Could MCH explain vivid dreams during certain medications or conditions?
Possibly. Conditions or medications that alter MCH neuron activity could affect REM sleep and thereby dream intensity. Some antidepressants (which suppress REM) might do so partly through MCH circuit effects, and REM rebound after stopping them could involve MCH overactivity. These connections are speculative and not yet tested.
How does MCH fit with the other sleep peptides in this cluster?
Cluster J contains a complete map of peptide sleep regulation. Orexin promotes wakefulness (DORAs block it for insomnia). MCH promotes REM sleep (MCHR1 antagonists may block REM intrusions in narcolepsy). Galanin promotes NREM/SWS through the VLPO. Cortistatin deepens slow-wave oscillations. Desmopressin prevents nocturia. CRH disrupts sleep via stress activation. Together, they illustrate how different neuropeptides control different sleep stages and functions.
Summary of Key Findings
Melanin-concentrating hormone is the neuropeptide of REM sleep. Its neurons fire exclusively during REM, optogenetic activation selectively increases REM without affecting other sleep stages, and its receptor blockade nearly eliminates cataplexy in narcolepsy models. The biology is as clean as sleep neuroscience gets—a single peptide, a single receptor, a single sleep stage.
The therapeutic translation has been disappointing. Obesity programs using MCHR1 antagonists failed in the 2000s. The narcolepsy program (HBS-102, Harmony Biosciences) was announced in 2021 but has not reported clinical data. No MCH-targeting drug has been tested in a human sleep study. The dual role in REM sleep and appetite creates pharmacological complexity—any MCHR1 antagonist will affect both.
For Peptidings readers, MCH is the complement to orexin in the lateral hypothalamus—two intermingled neuron populations with opposite functions, one of which (orexin) has generated three FDA-approved drugs and the other (MCH) has generated none. The biology is proven. The pharmacology is pending.
Verdict Recapitulation
Evidence Tier 4 — Preclinical Only. No human clinical data for MCH modulation in sleep or any other indication. Definitive optogenetic evidence in animal models.
Verdict: Eyes Open. MCH controls REM sleep with a specificity unmatched by any other neuropeptide. The narcolepsy preclinical data is striking—MCHR1 antagonism nearly eliminated cataplexy. But the drug pipeline is silent and the translational gap is wide. The biology deserves a drug. The drug has not arrived.
For readers considering Melanin-Concentrating Hormone, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Melanin-Concentrating Hormone
Further Reading and Resources
If you want to go deeper on Melanin-Concentrating Hormone, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Melanin-Concentrating Hormone — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Jego S, et al. Optogenetic identification of a rapid eye movement sleep modulatory circuit in the hypothalamus. Nat Neurosci. 2013;16(11):1637–1643 PubMed
- Naganuma F, et al. Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy. Neurobiol Dis. 2018;120:12–20 PubMed
- Peyron C, et al. Melanin-concentrating hormone and sleep. Curr Opin Neurobiol. 2022;74:102561 PubMed
- Kawauchi H, et al. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature. 1983;305(5932):321–323
- Qu D, et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature. 1996;380(6571):243–247 PubMed
- Ludwig DS, et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest. 2001;107(3):379–386 PubMed
DISCLAIMER
Melanin-Concentrating Hormone is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.